(19)
(11) EP 2 010 151 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
11.01.2017 Bulletin 2017/02

(45) Mention of the grant of the patent:
12.10.2016 Bulletin 2016/41

(21) Application number: 07723330.2

(22) Date of filing: 16.03.2007
(51) International Patent Classification (IPC): 
A61K 9/127(2006.01)
 A61K 31/00(2006.01)
(86) International application number:
PCT/EP2007/002352
(87) International publication number:
WO 2007/107305 (27.09.2007 Gazette 2007/39)

(54)

TREATMENT OF TRIPLE RECEPTOR NEGATIVE BREAST CANCER

BEHANDLUNG VON DREIFACH-NEGATIVEM-RECEPTOR BRUSTKREBS

TRAITEMENT DU CANCER DU SEIN AVEC TRIPLE RÉCEPTEUR NÉGATIF

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

(30) Priority: 22.03.2006 EP 06005893

(43) Date of publication of application:
07.01.2009 Bulletin 2009/02

(60) Divisional application:
16158395.0 / 3056196

(73) Proprietor: SynCore Biotechnology CO., LTD
Tung Shan Shine, I-Lan (TW)

(72) Inventors:
  • KLICHE, Kay-Oliver
    82166 Gräfelfing (DE)
  • MESCHEDER, Axel
    82237 Wörthsee (DE)
  • PICCART, Martine
    B-1000 Brussels (BE)

(74) Representative: Weickmann & Weickmann PartmbB 
Postfach 860 820
81635 München
81635 München (DE)


(56) References cited: : 
WO-A-93/18751
WO-A-2006/117220
 WO-A-2005/039533
US-A- 5 415 869
   
  • REBECCA DENT ET AL.: "Triple Negative Breast Cancer: clinicl features and patterns of recurrence", CLIN. CANCER RES 2007, vol. 13, 27 August 2007 (2007-08-27), pages 4429-4434,
  • LISA A. CAREY ET AL.: "the triple negative paradox", CLIN CANCER RES, vol. 13, 27 August 2007 (2007-08-27), pages 2329-2334,
  • CHRISTOS SOTIRIOU ET AL.: "Breast cancer classification", PNAS, vol. 100, no. 18, 2 September 2003 (2003-09-02), pages 10393-10398,
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).